Chapter

Positron Emission Tomography: A Critical Assessment of Recent Trends

Volume 51 of the series NATO ASI Series pp 91-98

Development of PET Radioligands for the Quantitation of Serotonin Receptors in the Human Brain

  • Christer HalldinAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Lars FardeAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Camilla LundkvistAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Hiroshi ItoAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Nathalie GinovartAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Håkan HallAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Svante NybergAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Carl-Gunnar SwahnAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
  • , Göran SedvallAffiliated withKarolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital
    • , Julie A. McCarronAffiliated withCyclotron Unit, MRC Clinical Sciences Centre, Hammersmith Hospital
    • , Victor W. PikeAffiliated withCyclotron Unit, MRC Clinical Sciences Centre, Hammersmith Hospital

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Pharmacological studies have shown that there are multiple serotonin receptor subtypes, which are classified in at least seven classes. [1]. There has been a lack of subtype selective serotonin receptor radioligands suitable for PET imaging of the human brain. The 5-HT1a receptor is of particular interest as it may be involved in the pathophysiology of several neuropsychiatric disorders, like anxiety, depression and schizophrenia. Recently, a potent and selective 5-HT1a receptor antagonist, WAY-100635 (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl)cyclohexanecarboxamide) was developed. Labelling of WAY-100635 in the methoxy position with 11C [2–3] provided the first radioligand for the delineation of 5-HT1a receptors in the human brain using positron emission tomography (PET) [4]. The descyclohexanecarbonyl analogue ([11C]WAY- 100634) was shown to be a labelled lipophilic metabolite in primates with high affinity to 5-HTlA receptors and high ability to enter the brain, so hampering the quantitation of the uptake of the radioligand in vivo [5]. WAY-100635 has recently been labelled with 11C also in the carbonyl position and examined in the human brain with PET [6].